Literature DB >> 21463177

Prevalence of multiple sclerosis in Dubai, United Arab Emirates.

Jihad Inshasi1, Mona Thakre.   

Abstract

BACKGROUND: The prevalence of multiple sclerosis (MS) is rapidly changing.
OBJECTIVES: To determine the prevalence and incidence of MS in Dubai, UAE.
METHODS: Data for all MS patients fulfilling McDonald criteria and registered in the Neurology Department, Rashid Hospital, Dubai between January 01, 2000 to December 12, 2007 were analyzed.
RESULTS: Two hundred and eighty-four MS patients were identified of which 158 (55.6%) were Dubai Natives and 126 (44.4%) Immigrants. In the Dubai Native population, the female to male ratio was 2.85:1. Motor manifestation was the commonest presentation 72.78% followed by sensory symptom 48.41%. The median and mean expanded disability status scale (EDSS) was 1.5 and 2.38 respectively. The mean age of onset was 26.66 ± 6.6 years. The prevalence of MS in 2007 was 54.77/100,000 (95% C.I. 46.99-62.55) with an annual incidence rate of 6.8/100,000 (95% C.I. 3.8-9.87) during 2000-2007.
CONCLUSION: Dubai should be considered as one of the regions with medium to high risk for MS, with prevalence rate higher than what has been previously believed. This high MS incidence and prevalence in Dubai is surprising and it may represent a true increase. Central MS registry and long-term follow-up epidemiological studies are recommended.

Entities:  

Mesh:

Year:  2011        PMID: 21463177     DOI: 10.3109/00207454.2011.565893

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  19 in total

1.  Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.

Authors:  Esraa Q Alsaedi; Marwa Q Alsaedi; Farah A Mansuri
Journal:  Cureus       Date:  2022-06-11

2.  Multiple Sclerosis, Anxiety, and Depression in the United Arab Emirates: Does Social Stigma Prevent Treatment?

Authors:  Nicoline Schiess; Katherine Huether; Kathryn B Holroyd; Faisal Aziz; Essam Emam; Tarek Shahrour; Miklos Szolics; Taoufik Alsaadi
Journal:  Int J MS Care       Date:  2019 Jan-Feb

3.  Serum 25(OH) Vitamin D levels is not associated with disability in multiple sclerosis patients: A case-control study.

Authors:  Masoud Nikanfar; Ali Akbar Taheri-Aghdam; Maria Yazdani; Sheida Shaafi; Nooshin Masoudian; Hossein Akbari; Parisa Youhanaee; Hamzeh Abbaszadeh
Journal:  Iran J Neurol       Date:  2015-01-05

4.  Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Authors:  Mohammed Aljumah; Raed Alroughani; I Alsharoqi; Saeed A Bohlega; Maurice Dahdaleh; Dirk Deleu; Khaled Esmat; Ahmad Khalifa; Mohammad A Sahraian; Miklós Szólics; Abdulrahman Altahan; Bassem I Yamout; Peter Rieckmann; Abdulkader Daif
Journal:  Mult Scler Int       Date:  2013-12-17

5.  Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis?

Authors:  Hamidreza Hatamian; Elham Bidabadi; Seyed Mohammad Seyed Saadat; Niloufar Seyed Saadat; Ehsan Kazemnezhad; Hamed Ramezani; Babak Bakhshayesh
Journal:  Iran J Neurol       Date:  2013

6.  Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.

Authors:  Anat Achiron; Hany Aref; Jihad Inshasi; Mohamad Harb; Raed Alroughani; Mahendra Bijarnia; Kathryn Cooke; Ozgur Yuksel
Journal:  BMC Neurol       Date:  2017-08-07       Impact factor: 2.474

7.  Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018.

Authors:  Raed Alroughani; Tomas Kalincik; Nahid Moradi; Sifat Sharmin; Charles Malpas; Serkan Ozakbas; Vahid Shaygannejad; Murat Terzi; Cavit Boz; Bassem Yamout; Recai Turkoglu; Rana Karabudak; Sherif Hamdy; Aysun Soysal; Ayşe Altıntaş; Jihad Inshasi; Talal Al-Harbi
Journal:  CNS Drugs       Date:  2021-06-23       Impact factor: 5.749

Review 8.  Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Authors:  Raed A Alroughani; Hany M Aref; Saeed A Bohlega; Maurice P Dahdaleh; Imed Feki; Mohammed A Al Jumah; Muhammad Z Al-Kawi; Salam F Koussa; Mohamad A Sahraian; Isa A Alsharoqi; Bassem I Yamout
Journal:  BMC Neurol       Date:  2014-02-12       Impact factor: 2.474

Review 9.  Notes on the epidemiology of multiple sclerosis, with special reference to dietary habits.

Authors:  Klaus Lauer
Journal:  Int J Mol Sci       Date:  2014-02-26       Impact factor: 5.923

Review 10.  Multiple sclerosis in the Arabian Gulf countries: a consensus statement.

Authors:  Saeed Bohlega; Jihad Inshasi; Abdel Rahman Al Tahan; Abu Bakr Madani; Hussien Qahtani; Peter Rieckmann
Journal:  J Neurol       Date:  2013-03-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.